- Home
- A-Z Publications
- Current Pharmaceutical Biotechnology
- Previous Issues
- Volume 1, Issue 4, 2000
Current Pharmaceutical Biotechnology - Volume 1, Issue 4, 2000
Volume 1, Issue 4, 2000
-
-
Antibody-Targeted Immunotherapy for Treatment of Non-Hodgkins Lymphoma
Authors: C.A. White, J.R. Berlfein and A.J. Grillo-LopezThe scientific development of immunotherapies and radioimmunotherapies of cancer began more than four decades ago. Over time, it has become apparent that the choice of target antigen, immunogenicity of antibodies, length of antibody half-life, ability of antibodies to recruit immune effector functions, decision on conjugation of antibodies to toxins or radionuclides and antibody manufacturing are critical com Read More
-
-
-
Controlled Delivery of Biotechnological Products
Authors: S. Conti, L. Polonelli, R. Frazzi, M. Artusi, R. Bettini, D. Cocconi and P. ColomboPeptides, proteins, and nucleotides or DNA fragments are the new generation of drugs. They are becoming attractive owing to the fast development of biotechnology. The admnistration of such molecules, however, may be a problem as sensitivity to temperature, instability at some physiological pH values, short plasma half-life, and high molecular dimension, which hinders the diffusive transport, make, at the momen Read More
-
-
-
Mitochondriotropic Cationic Vesicles A Strategy Towards Mitochondrial Gene Therapy
Authors: V. Weissig and V.P. TorchilinThe number of diseases found to be associated with defects of the mitochondrial genome has grown significantly over the last decade. Despite major advances in understanding mtDNA defects at the genetic and biochemical level, there is no satisfactory treatment for the vast majority of patients available. This is largely due to the fact that almost all mitochondrial DNA defects involve the final common pathway of oxidativ Read More
-
-
-
N-Glycosylation of Recombinant Pharmaceutical Glycoproteins Produced in Transgenic Plants Towards an Humanisation of Plant N-Glycans
Authors: P. Lerouge, M. Bardor, S. Pagny, V. Gomord and L. FayeThe number of therapeutic proteins successfully produced in plants is steadily increasing and is expected to grow even more rapidly in the future. Most therapeutic proteins are glycoproteins and N-glycosylation is often essential for their stability, folding and biological activity. Recombinant glycoproteins of mammalian origin expressed in transgenic plants largely retain their biological activity. However, plants are not ideal for Read More
-
-
-
Structure Alteration of Polyketides by Recombinant DNA Technology in Producer Organisms Prospects for the Generation of Novel Pharmaceutical Drugs.
Authors: C. Mendez, G. Weitnauer, A. Bechthold and J.A. SalasActinomycetes are gram-positive bacteria and commercially important microorganisms. They are producers of approximately two thirds of all bioactive compounds known and they produce a great variety of compounds which have clinical application on the basis of their activity against different kinds of organisms and cells as antibacterial (macrolides, avermectins), antitumor (anthracyclines, angucyclines, aureolic acid Read More
-
Volumes & issues
-
Volume 26 (2025)
-
Volume 25 (2024)
-
Volume 24 (2023)
-
Volume 23 (2022)
-
Volume 22 (2021)
-
Volume 21 (2020)
-
Volume 20 (2019)
-
Volume 19 (2018)
-
Volume 18 (2017)
-
Volume 17 (2016)
-
Volume 16 (2015)
-
Volume 15 (2014)
-
Volume 14 (2013)
-
Volume 13 (2012)
-
Volume 12 (2011)
-
Volume 11 (2010)
-
Volume 10 (2009)
-
Volume 9 (2008)
-
Volume 8 (2007)
-
Volume 7 (2006)
-
Volume 6 (2005)
-
Volume 5 (2004)
-
Volume 4 (2003)
-
Volume 3 (2002)
-
Volume 2 (2001)
-
Volume 1 (2000)
Most Read This Month
Article
content/journals/cpb
Journal
10
5
false
en
